Trial Profile
The Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary)
- Indications Angina pectoris; Hyperuricaemia
- Focus Therapeutic Use
- 02 Aug 2017 Status changed from not yet recruiting to discontinued as Entry were insufficient as expected.
- 06 Nov 2014 New trial record